News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
581,750 Results
Type
Article (42137)
Company Profile (309)
Press Release (539304)
Section
Business (167179)
Career Advice (2431)
Deals (30259)
Drug Delivery (90)
Drug Development (78416)
Employer Resources (147)
FDA (14291)
Job Trends (12931)
News (295081)
Policy (28544)
Tag
Academia (2659)
Africa (742)
Alliances (42615)
Alzheimer's disease (1216)
Antibody-drug conjugate (ADC) (63)
Approvals (14211)
Arizona (125)
Artificial intelligence (89)
Asia (35513)
Australia (7058)
Bankruptcy (315)
Best Places to Work (10403)
Biotechnology (251)
Breast cancer (75)
C2C Services and Suppliers (55895)
California (2054)
Canada (961)
Cancer (647)
Career advice (2041)
Cell therapy (161)
China (155)
Clinical research (61372)
Collaboration (198)
Colorado (82)
Compensation (93)
Connecticut (81)
COVID-19 (2483)
Cystic fibrosis (80)
Data (478)
Diabetes (95)
Diagnostics (5497)
Drug pricing (79)
Earnings (59222)
Employer resources (132)
Europe (79334)
Events (86365)
Executive appointments (192)
FDA (14585)
Florida (284)
Funding (189)
Gene therapy (119)
GLP-1 (554)
Government (4160)
Healthcare (17108)
Hotbed/Location (389373)
Illinois (245)
Indiana (142)
Infectious disease (2527)
Inflammatory bowel disease (101)
Interviews (521)
IPO (13996)
Job creations (2738)
Job search strategy (1685)
Kansas (84)
Layoffs (393)
Legal (6007)
Lung cancer (134)
Manufacturing (105)
Maryland (420)
Massachusetts (1589)
Medical device (10890)
Medtech (10894)
Mergers & acquisitions (16202)
Metabolic disorders (298)
Michigan (122)
Minnesota (199)
Neuroscience (1416)
New Jersey (617)
New York (642)
NextGen Class of 2024 (5910)
Non-profit (4111)
North Carolina (591)
Northern California (883)
Obesity (176)
Ohio (102)
Opinion (201)
Patents (83)
Pennsylvania (548)
People (52720)
Phase I (19160)
Phase II (27086)
Phase III (20267)
Pipeline (140)
Policy (66)
Postmarket research (2381)
Preclinical (8098)
Radiopharmaceuticals (240)
Rare diseases (161)
Real estate (4480)
Regulatory (19417)
Research institute (2260)
Resumes & cover letters (358)
South America (1018)
Southern California (849)
Startups (3164)
Texas (258)
United States (8815)
Vaccines (472)
Washington State (249)
Weight loss (152)
Date
Today (103)
Last 7 days (566)
Last 30 days (2498)
Last 365 days (34871)
2024 (26274)
2023 (37503)
2022 (48407)
2021 (52037)
2020 (50010)
2019 (42513)
2018 (32046)
2017 (29625)
2016 (28219)
2015 (32950)
2014 (25391)
2013 (20579)
2012 (21802)
2011 (22728)
2010 (20440)
581,750 Results for "cascadian therapeutics formally known as oncothyreon".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Business
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Chromocell Therapeutics Corp. today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
March 21, 2024
·
5 min read
Pharm Country
Perseus Therapeutics Announces Development of TSLP Antibody for Prevention of Hair Loss in Cancer Patients and Treatment of Inflammatory Diseases with well-known CRO partner
Perseus Therapeutics, a pioneering biopharmaceutical company based in New York City, is proud to announce the development of a novel thymic stromal lymphopoietin (TSLP) antibody aimed at preventing hair loss in cancer patients and treating a range of inflammatory diseases, including asthma.
May 22, 2024
·
2 min read
Press Releases
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
August 13, 2024
·
5 min read
Business
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.
April 15, 2024
·
3 min read
Drug Development
Genetesis Formally Launches MICRO2 Trial with Announcement of First Patient Enrollment
July 3, 2024
·
4 min read
Press Releases
Asthma Therapeutics Market Size to Reach USD 22.0 Billion by 2032, Impelled by Favorable Government Initiatives
Asthma Therapeutics Market Outlook 2024-2032:
August 8, 2024
·
10 min read
FDA
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.
March 8, 2024
·
14 min read
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Press Releases
Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities
July 23, 2024
·
6 min read
1 of 58,175
Next